UNSPSC 51181538: Fidarestat

This classification denotes a cyp11b2 gene with the molecular formula C12H10FN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8SH8T1164U, chemically known as spiro(4h-1-benzopyran-4,4-imidazolidine)-2-carboxamide, 6-fluoro-2,3-dihydro-2,5-dioxo-, (2s-cis)- but generally known as fidarestat, which bears US NIH Compound Identifier 160024. European Medicines Agency schedules Fidarestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07624MIG.

UNSPSC 51181538 Fidarestat is a Commodity code for a specific pharmaceutical active ingredient; state and local procurement activity under this code centers on generic multi-source pharmaceutical procurement through cooperative purchasing vehicles that aggregate demand across state agencies, local health systems, and participating jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, drives the visible recent activity, soliciting manufacturers and authorized distributors to supply comprehensive pharmaceutical product lines including generic versions and over-the-counter products to state and local government facilities. Work under this code involves establishing contractual relationships with pharmaceutical manufacturers, managing National Drug Codes (NDCs) and product specifications, coordinating with authorized wholesalers (such as AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), certifying compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and maintaining pricing structures negotiated through cooperative agreements. State health agencies, correctional systems, public health departments, and local government clinics are the primary end-users, though procurement is typically consolidated through state-level cooperative purchasing offices rather than issued by individual counties or municipalities.

The code shows activity centered in Minnesota and Oregon, with MMCAP representing the dominant recent solicitation vehicle. Minnesota's MMCAP issued a Request for Proposal (RFP) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026; evaluations weight price competitiveness at 75 percent, fixed pricing at 10 percent, and compliance with EDI capability, administrative fee format, and chargeback system requirements at 5 percent each. Awarded vendors must maintain insurance including $5 million commercial general liability, demonstrate pricing flexibility through flat-price, net-price, or WAC-minus structures, and manage three-percent administrative fees levied on all contract purchases. The contract term is two years for new responders with optional extensions, effective July 1, 2026, with specific award values undisclosed in the procurement materials.